000			01811cam a22004694a 4500
001			15472966
003			OSt
005			20230220110912.0
008			080925s2008 njua b 001 0 eng c
010			_a 2008938265 _z 2008938268
015			_aGBA871787 _2bnb
016	7		_a101493871 _2DNLM
016	7		_a014627855 _2Uk
020			_a1617376948
035			_a(OCoLC)ocn166358032
040			_aNLM _cNLM _dUKM _dBTCTA _dBAKER _dYDXCP _dBWX _dLTL _dDLC _dIG# _dDLC
042			_apcc
050	0	0	_aRC271 _b.G46 2010
245	0	0	_aGenomics and pharmacogenomics in anticancer drug development and clinical response / _cedited by Federico Innocenti.
260			_aTotowa, NJ : _bHumana, _c2010
300			_axiv, 379p. :
490	1		_aCancer drug discovery and development
504			_aIncludes bibliographical references and index.
505	0		_aGenomic experimental approaches in oncology -- Pharmacogenomics of toxicity and response of chemotherapy -- Pharmacogenomics in clinical drug development in oncology.
650		0	_aCancer _xGenetic aspects.
650		0	_aCancer _xMolecular aspects.
650		0	_aGenomics.
650		0	_aPharmacogenomics.
650		0	_aDrug development.
650		0	_aAntineoplastic agents _xDevelopment.
650	1	2	_aAntineoplastic Agents.
650	2	2	_aGenomics.
650	2	2	_aNeoplasms _xdrug therapy.
650	2	2	_aNeoplasms _xgenetics.
650	2	2	_aPharmacogenetics _xmethods.
700	1		_aInnocenti, Federico.
830		0	_aCancer drug discovery and development.
906			_a7 _bcbc _cpccadap _d2 _eepcn _f20 _gy-gencatlg
942			_2lcc _cBK
999			_c20002 _d20001